Amylyx Pharmaceuticals, Inc. filings document a clinical-stage biotechnology issuer developing investigational therapies in endocrine conditions and neurodegenerative diseases. Its 8-K reports furnish quarterly and annual financial results, corporate presentations and material-event disclosures tied to programs such as avexitide for post-bariatric hypoglycemia, AMX0318 and AMX0035.
Proxy and material-event filings describe governance, executive compensation, shareholder voting matters, common-stock registration on the Nasdaq Global Select Market, capital-structure matters, material agreements and program decisions. These records also capture collaboration economics, development-candidate selections, expanded pipeline disclosures and formal updates to clinical programs.
Amylyx Pharmaceuticals Inc ownership disclosure: The Vanguard Group filed an amendment noting it beneficially owns 0 shares of Common Stock, representing 0% of the class.
The filing states Vanguard reorganized on January 12, 2026 and, in accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries will report separately and Vanguard no longer is deemed to beneficially own those securities.
Amylyx Pharmaceuticals furnished an updated corporate presentation outlining progress across its rare disease pipeline and financial position. The company highlighted completion of enrollment in the Phase 3 LUCIDITY trial of avexitide for post-bariatric hypoglycemia, with topline data expected in Q3 2026 and a potential commercial launch in 2027 if approved.
The presentation also noted completion of enrollment in Cohort 2 of the Phase 1 LUMINA trial of AMX0114 for ALS, positive Phase 2 HELIOS results for AMX0035 in Wolfram syndrome, and nomination of AMX0318 as a long-acting GLP-1 receptor antagonist development candidate. As of December 31, 2025, Amylyx reported $317 million in cash, cash equivalents, and short-term investments and approximately 110 million shares outstanding, with a cash runway expected into 2028 through the potential approval and launch of avexitide in 2027.
Cohen Joshua B reported acquisition or exercise transactions in this Form 4 filing.
Amylyx Pharmaceuticals Co-Chief Executive Officer Joshua B. Cohen reported equity awards consisting of 248,865 shares of common stock from a restricted stock unit grant and a stock option covering 373,295 shares. The RSUs vest in four equal annual installments starting on March 1, 2027, while 25% of the option vests on that date and the remainder vests monthly over the following 36 months, all subject to his continued service.
Amylyx Pharmaceuticals Chief Legal Officer receives new equity awards. On March 5, 2026, Gina Mazzariello was granted stock options for 111,990 shares at an exercise price of $0.00 per share and an award of 74,660 shares of common stock in the form of restricted stock units.
The RSU award vests in four equal annual installments starting March 1, 2027, contingent on continued service. The stock option vests with 25% on March 1, 2027 and the remainder monthly over the next 36 months, also subject to continued service. Following these awards, she directly holds 209,090 shares of common stock.
Amylyx Pharmaceuticals Chief Financial Officer James M. Frates reported equity compensation awards in the form of stock options and restricted stock units. On March 5, 2026, he was granted stock options for 143,985 shares at an exercise price of $0.00 per share, and a separate grant of 95,990 shares of common stock as a restricted stock unit award.
The RSUs vest in four equal annual installments starting on March 1, 2027, subject to his continued service. Twenty‑five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also subject to continued service. Additional common shares are held indirectly by various family trusts for which he serves as trustee, and he disclaims beneficial ownership of those shares except to the extent of any pecuniary interest.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported equity awards from the company. He received a stock option for 373,295 shares at an exercise price of $0.0000 per share and a grant of 248,865 shares of common stock as restricted stock units (RSUs).
The RSUs vest in four equal annual installments starting on March 1, 2027, conditioned on his continued service. The option vests 25% on March 1, 2027, with the remaining shares vesting monthly over the next 36 months, also subject to continued service. After these grants, he reported owning 3,583,481 shares of common stock directly.
Amylyx Pharmaceuticals granted Chief Medical Officer Camille L. Bedrosian equity awards on March 5, 2026. She received stock options for 143,985 shares at an exercise price of $0.00 and 95,990 shares of common stock as a restricted stock unit award.
The RSUs vest in four equal annual installments starting on March 1, 2027, subject to continued service. Twenty-five percent of the option vests on March 1, 2027, with the remainder vesting monthly over the following 36 months, also contingent on ongoing service.
Amylyx Pharmaceuticals Co-Chief Executive Officer Justin B. Klee reported an open-market sale of common stock tied to tax withholding. On March 2, he sold 29,282 shares at a weighted average price of $14.4717 per share to cover withholding obligations from vesting restricted stock units. The filing notes these sales were automatic and not at his discretion, and he continued to hold 3,334,616 shares of Amylyx common stock directly after the transaction.
Amylyx Pharmaceuticals director and Co-CEO Joshua B. Cohen reported an automatic tax-related share sale. On March 2, 2026, 29,282 shares of common stock were sold at a weighted average price of $14.484 per share to cover tax withholding owed on vesting restricted stock units.
The filing notes these sales were required to satisfy withholding obligations and were not made at Cohen’s discretion. After the transaction, he continues to directly own 3,334,683 shares of Amylyx common stock, indicating he retains a substantial equity stake in the company.
Amylyx Pharmaceuticals Chief Medical Officer Camille L. Bedrosian reported an automatic sale of 6,461 shares of common stock on March 2, 2026 to cover tax withholding obligations arising from the vesting of restricted stock units. The shares were sold at a weighted average price of $14.5806 per share in multiple trades between $14.440 and $14.945. After these tax-related sales, Bedrosian held 169,295 shares of Amylyx common stock directly.